Dual Antiplatelet Therapy for Cardiovascular Protection
Brilinta (ticagrelor) 90 mg twice daily combined with low-dose aspirin 81 mg daily is prescribed to prevent blood clots that cause heart attacks, strokes, and cardiovascular death in patients with acute coronary syndromes (ACS) or high-risk coronary artery disease. This combination therapy, called dual antiplatelet therapy (DAPT), works by blocking two different pathways of platelet activation—aspirin inhibits thromboxane A2 production while ticagrelor directly and reversibly blocks the P2Y12 receptor 1, 2.
Why This Combination Works
The rationale for combining these medications is straightforward: platelets can be activated through multiple pathways, and blocking just one pathway leaves patients vulnerable to thrombotic events. Aspirin alone provides incomplete protection, which is why adding a P2Y12 inhibitor like ticagrelor significantly reduces major adverse cardiovascular events (MACE) including death, heart attack, and stroke 1.
Ticagrelor offers several advantages over clopidogrel (Plavix):
- Faster onset of action (within 30 minutes vs. several hours)
- More consistent and potent platelet inhibition across patients
- No genetic variability issues (doesn't require metabolic conversion like clopidogrel)
- Reversible binding allowing faster recovery of platelet function when needed 3
The Critical Aspirin Dose
When taking ticagrelor, aspirin must be limited to 81 mg (or 75-100 mg) daily—higher doses reduce ticagrelor's effectiveness 1, 4, 2. This is a crucial distinction from other P2Y12 inhibitors where aspirin doses up to 325 mg are acceptable. The FDA label explicitly states: "daily doses of aspirin should not exceed 100 mg" when combined with ticagrelor 2.
The mechanism behind this interaction relates to high-dose aspirin potentially suppressing prostacyclin (a natural antiplatelet substance) while not providing additional antiplatelet benefit, thereby creating a prothrombotic environment that counteracts ticagrelor's effects 5.
Clinical Indications
This combination is specifically indicated for 1, 6:
- Acute coronary syndromes (unstable angina, NSTEMI, STEMI) - for at least 12 months
- Post-PCI with stent placement - minimum 12 months for drug-eluting stents
- High-risk stable coronary artery disease - in selected patients with prior MI and additional risk factors
- Acute ischemic stroke or TIA - for stroke prevention in certain cases
Duration of Therapy
Standard duration is 12 months after ACS or stent placement 1, 4, 7. Beyond 12 months, continuation may be considered in high ischemic risk patients without high bleeding risk, though this requires careful individualized assessment of thrombotic versus bleeding risk 1, 6.
Important Safety Considerations
The primary risk is bleeding—patients will bruise more easily, bleed longer, and face increased risk of serious hemorrhage 2. Major bleeding occurs in approximately 0.5% more patients on ticagrelor compared to placebo, though this is balanced by significant reductions in cardiovascular death 2.
Critical warnings:
- Never stop ticagrelor abruptly without consulting your physician—premature discontinuation dramatically increases risk of stent thrombosis, heart attack, and death 2
- Stop ticagrelor 5 days before elective surgery (vs. 7 days for prasugrel) 8, 9
- Contraindicated in patients with prior intracranial hemorrhage or active bleeding 2
- Report any severe, uncontrolled, or unusual bleeding immediately
Common Pitfalls to Avoid
- Taking aspirin doses >100 mg with ticagrelor - this reduces efficacy 2, 5
- Taking additional aspirin-containing medications - many over-the-counter products contain aspirin 2
- Stopping medication due to minor bleeding or bruising - discuss with physician before discontinuing as benefits typically outweigh minor bleeding risks 2
- Missing doses - ticagrelor requires twice-daily dosing for consistent platelet inhibition 2
Practical Administration
- Take ticagrelor 90 mg twice daily (morning and evening, approximately 12 hours apart)
- Take aspirin 81 mg once daily
- Can be taken with or without food
- If you miss a dose, take the next scheduled dose—do not double up 2
The combination of ticagrelor and low-dose aspirin represents a potent, evidence-based strategy to prevent life-threatening cardiovascular events, with the critical caveat that aspirin dosing must remain at or below 100 mg daily to maintain ticagrelor's full protective effect.